Skip to main content

Table 1 Study samples (DNA extracted from culture isolates) and their susceptibility to anti-tuberculosis drugs

From: The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs

Sample

Yeara

Lineage

Spoligo. family

Drug susceptibility test phenotype

INH

RIF

STR

ETB

PZA

RFB

ETH

AMK

CAP

OFX

MOX

PAS

LZ

KANb

Resistance phenotype

POR1

2007

4.3.4.2

LAM4

R

R

R

R

R

R

R

R

R

R

R

R

S

R

XDR-TB

POR2

2007

4.1.1.1

X2

R

R

S

S

S

R

R

S

S

S

S

S

S

-

MDR-TB

POR3

2007

4.3.4.2

LAM1

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR-TB

POR4

2007

4.3.4.2

LAM1

R

R

R

R

R

R

R

R

S

R

R

S

S

R

XDR-TB

POR5

2007

4.3.4.2

LAM4

R

R

R

R

R

R

R

S

S

S

S

S

S

-

MDR-TB

POR6

2008

4.3.4.2

LAM4

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR-TB

POR7

2009

4.3.4.2

LAM4

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR-TB

POR8

2012

4.3.4.2

LAM4

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR-TB

POR9

2011

4.3.4.2

LAM4

R

R

R

R

R

R

R

R

R

R

R

R

S

R

XDR-TB

POR10

2013

4.2.1

Ural H3/4

R

R

R

R

R

R

R

S

S

S

S

S

S

R

MDR-TB

H37Rv

-

4.9

H37RV

S

S

S

S

S

S

S

S

S

S

S

S

S

-

Pan-susceptible

  1. MDR-TB multidrug-resistant TB, XDR-TB extensively drug-resistant TB, INH isoniazid, RIF rifampicin, STR streptomycin, ETB ethambutol, PZA pyrazinamide, RFB rifabutin, ETH ethionamide, AMK amikacin, CAP capreomycin, OFX ofloxacin, MOX moxifloxacin, PAS para-aminosalicylic acid, LZ linezolid, KAN kanamycin, S “susceptible”, R “resistant”
  2. Bold indicates discrepant calls by Mykrobe Predictor, underlining indicates discrepant calls by TBProfiler
  3. aYear of collection
  4. bDrug susceptibility test not performed, with status inferred by the TBProfiler library